Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...